Stephen T. Gancher

2.4k total citations · 1 hit paper
28 papers, 1.7k citations indexed

About

Stephen T. Gancher is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Stephen T. Gancher has authored 28 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Neurology, 11 papers in Cellular and Molecular Neuroscience and 6 papers in Molecular Biology. Recurrent topics in Stephen T. Gancher's work include Parkinson's Disease Mechanisms and Treatments (21 papers), Neurological disorders and treatments (14 papers) and Epilepsy research and treatment (5 papers). Stephen T. Gancher is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (21 papers), Neurological disorders and treatments (14 papers) and Epilepsy research and treatment (5 papers). Stephen T. Gancher collaborates with scholars based in United States, Spain and United Kingdom. Stephen T. Gancher's co-authors include John G. Nutt, William R. Woodward, E. R. Brunt, Eric A. Smith, D.L. Browne, M. Litt, Patricia Kramer, John G. Nutt, Brian Boucher and John P. Hammerstad and has published in prestigious journals such as Nature Genetics, Neurology and Annals of Neurology.

In The Last Decade

Stephen T. Gancher

27 papers receiving 1.7k citations

Hit Papers

Episodic ataxia/myokymia syndrome is associated with poin... 1994 2026 2004 2015 1994 100 200 300 400 500

Peers

Stephen T. Gancher
Linda Vedders United States
Khashayar Dashtipour United States
Hermann Russ Germany
David Swope United States
Linda Vedders United States
Stephen T. Gancher
Citations per year, relative to Stephen T. Gancher Stephen T. Gancher (= 1×) peers Linda Vedders

Countries citing papers authored by Stephen T. Gancher

Since Specialization
Citations

This map shows the geographic impact of Stephen T. Gancher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen T. Gancher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen T. Gancher more than expected).

Fields of papers citing papers by Stephen T. Gancher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen T. Gancher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen T. Gancher. The network helps show where Stephen T. Gancher may publish in the future.

Co-authorship network of co-authors of Stephen T. Gancher

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen T. Gancher. A scholar is included among the top collaborators of Stephen T. Gancher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen T. Gancher. Stephen T. Gancher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnson, Steven W., Stephen T. Gancher, & William R. Woodward. (1997). Digoxin prevents MPTP-induced dopamine depletion in mouse striatum. Neurotoxicology and Teratology. 19(5). 413–415. 1 indexed citations
2.
Gancher, Stephen T., et al.. (1997). The effect of nigral implantation on sensitization to dopamine agonists in 6-hydroxydopamine-lesioned rats. Neuroscience. 79(4). 963–972. 1 indexed citations
3.
Gancher, Stephen T., William R. Woodward, & John G. Nutt. (1996). Apomorphine Tolerance in Parkinson's Disease: Lack of a Dose Effect. Clinical Neuropharmacology. 19(1). 59–64. 18 indexed citations
4.
Gancher, Stephen T., et al.. (1996). Changes in apomorphine pharmacodynamics following repeated treatment in 6-hydroxydopamine-lesioned rats. Brain Research. 729(2). 190–196. 7 indexed citations
5.
Gancher, Stephen T., John G. Nutt, & William R. Woodward. (1995). Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance. Movement Disorders. 10(1). 37–43. 73 indexed citations
6.
Browne, D.L., E. R. Brunt, Robert C. Griggs, et al.. (1995). Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Human Molecular Genetics. 4(9). 1671–1672. 74 indexed citations
7.
Gancher, Stephen T., et al.. (1995). Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response. Brain Research. 682(1-2). 63–68. 22 indexed citations
8.
Gancher, Stephen T., et al.. (1995). Dose- and duration-dependent tolerance to rotational effects of apomorphine in a rat model of Parkinsonism.. Journal of Pharmacology and Experimental Therapeutics. 272(1). 275–281. 9 indexed citations
9.
Browne, D.L., Stephen T. Gancher, & John G. Nutt. (1994). Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene-KCNA1 (Kv1.1). The American Journal of Human Genetics. 55.
10.
Browne, D.L., Stephen T. Gancher, John G. Nutt, et al.. (1994). Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nature Genetics. 8(2). 136–140. 561 indexed citations breakdown →
11.
Hammerstad, John P., et al.. (1994). Controlled Release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100). Clinical Neuropharmacology. 17(5). 429–434. 15 indexed citations
12.
Nutt, John G., William R. Woodward, Charles K. Stone, et al.. (1994). Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44(5). 913–913. 208 indexed citations
13.
Nutt, John G., Julie H. Carter, William R. Woodward, John P. Hammerstad, & Stephen T. Gancher. (1993). Does tolerance develop to levodopa? Comparison of 2‐and 21‐h levodopa infusions. Movement Disorders. 8(2). 139–143. 16 indexed citations
14.
Irwin, Robert P., John G. Nutt, William R. Woodward, & Stephen T. Gancher. (1992). Pharmacodynamics of the Hypotensive Effect of Levodopa in Parkinsonian Patients. Clinical Neuropharmacology. 15(5). 365–374. 20 indexed citations
15.
Gancher, Stephen T., John G. Nutt, & William R. Woodward. (1992). Time course of tolerance to apomorphine in parkinsonism. Clinical Pharmacology & Therapeutics. 52(5). 504–510. 31 indexed citations
16.
Grandas, Francisco, Stephen T. Gancher, M. Rodriguez, et al.. (1992). Differences in the Motor Response to Apomorphine Between Untreated and Fluctuating Patients With Parkinsonʼs Disease. Clinical Neuropharmacology. 15(1). 13–18. 24 indexed citations
17.
Gancher, Stephen T., William R. Woodward, Perry M. Gliessman, Brian Boucher, & John G. Nutt. (1990). The short‐duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism. Annals of Neurology. 27(6). 660–665. 18 indexed citations
18.
Gancher, Stephen T., William R. Woodward, Brian Boucher, & John G. Nutt. (1989). Peripheral pharmacokinetics of apomorphine in humans. Annals of Neurology. 26(2). 232–238. 119 indexed citations
19.
Gancher, Stephen T., et al.. (1988). Movement disorders in multiple sclerosis. Movement Disorders. 3(2). 109–116. 23 indexed citations
20.
Gancher, Stephen T. & John G. Nutt. (1986). Autosomal dominant episodic ataxia: A heterogeneous syndrome. Movement Disorders. 1(4). 239–253. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026